165 related articles for article (PubMed ID: 32323602)
41. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
42. Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in the Iowa Women's Health Study cohort.
Leal AD; Thompson CA; Wang AH; Vierkant RA; Habermann TM; Ross JA; Mesa RA; Virnig BA; Cerhan JR
Int J Cancer; 2014 Apr; 134(7):1741-50. PubMed ID: 24114627
[TBL] [Abstract][Full Text] [Related]
43. Myeloid-derived suppressor cells in patients with myeloproliferative neoplasm.
Wang JC; Kundra A; Andrei M; Baptiste S; Chen C; Wong C; Sindhu H
Leuk Res; 2016 Apr; 43():39-43. PubMed ID: 26943702
[TBL] [Abstract][Full Text] [Related]
44. Management of symptoms in polycythemia vera and essential thrombocythemia patients.
Radia D; Geyer HL
Hematology Am Soc Hematol Educ Program; 2015; 2015():340-8. PubMed ID: 26637741
[TBL] [Abstract][Full Text] [Related]
45. Heterogeneity of the bone marrow niche in patients with myeloproliferative neoplasms: ActivinA secretion by mesenchymal stromal cells correlates with the degree of marrow fibrosis.
Rambaldi B; Diral E; Donsante S; Di Marzo N; Mottadelli F; Cardinale L; Dander E; Isimbaldi G; Pioltelli P; Biondi A; Riminucci M; D'Amico G; Elli EM; Pievani A; Serafini M
Ann Hematol; 2021 Jan; 100(1):105-116. PubMed ID: 33089365
[TBL] [Abstract][Full Text] [Related]
46. [Thrombosis in myeloproliferative neoplasms].
Asakura H
Rinsho Ketsueki; 2018; 59(8):1034-1041. PubMed ID: 30185703
[TBL] [Abstract][Full Text] [Related]
47. Epidemiology of the myeloproliferative disorders: essential thrombocythaemia, polycythaemia vera and idiopathic myelofibrosis.
Kutti J; Ridell B
Pathol Biol (Paris); 2001 Mar; 49(2):164-6. PubMed ID: 11317963
[TBL] [Abstract][Full Text] [Related]
48. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2019 Jan; 94(1):133-143. PubMed ID: 30281843
[TBL] [Abstract][Full Text] [Related]
49. The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey.
Harrison CN; Koschmieder S; Foltz L; Guglielmelli P; Flindt T; Koehler M; Mathias J; Komatsu N; Boothroyd RN; Spierer A; Perez Ronco J; Taylor-Stokes G; Waller J; Mesa RA
Ann Hematol; 2017 Oct; 96(10):1653-1665. PubMed ID: 28780729
[TBL] [Abstract][Full Text] [Related]
50. Prevalence and risk factors for Pulmonary Hypertension associated with chronic Myeloproliferative Neoplasms.
Ferrari A; Scandura J; Masciulli A; Krichevsky S; Gavazzi A; Barbui T
Eur J Haematol; 2021 Feb; 106(2):250-259. PubMed ID: 33135220
[TBL] [Abstract][Full Text] [Related]
51. Age-Related Macular Degeneration in Patients With Chronic Myeloproliferative Neoplasms.
Bak M; Sørensen TL; Flachs EM; Zwisler AD; Juel K; Frederiksen H; Hasselbalch HC
JAMA Ophthalmol; 2017 Aug; 135(8):835-843. PubMed ID: 28655032
[TBL] [Abstract][Full Text] [Related]
52. Dkk3 levels in patients with myeloproliferative neoplasms.
Medinger M; Muesser P; Girsberger S; Skoda R; Tzankov A; Buser A; Passweg J; Tsakiris DΑ
Thromb Res; 2014 Feb; 133(2):218-21. PubMed ID: 24309205
[TBL] [Abstract][Full Text] [Related]
53. Thrombosis in the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Sankar K; Stein BL; Rampal RK
Cancer Treat Res; 2019; 179():159-178. PubMed ID: 31317487
[TBL] [Abstract][Full Text] [Related]
54. Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger.
Szuber N; Vallapureddy RR; Penna D; Lasho TL; Finke C; Hanson CA; Ketterling RP; Pardanani A; Gangat N; Tefferi A
Am J Hematol; 2018 Dec; 93(12):1474-1484. PubMed ID: 30157297
[TBL] [Abstract][Full Text] [Related]
55. Highly increased risk of fracture in patients with myeloproliferative neoplasm.
Johansson P; Kristjansdottir HL; Johansson H; Jakir A; Mellström D; Lewerin C
Leuk Lymphoma; 2021 Jan; 62(1):211-217. PubMed ID: 32909485
[TBL] [Abstract][Full Text] [Related]
56. Philadelphia-negative chronic myeloproliferative neoplasm follow-up: when the phone rings. Changes during the COVID-19 pandemic and patient satisfaction. Experience in 30 health centers in Spain.
Ortuzar A; Fox ML; Vera JA; Lorenzo Vizcaya Á; Marín Sánchez A; Llopis Calatayud I; Carbonell S; Álvarez-Larrán A; Mata Serna R; Marco Buades JE; Quiroz Cervantes K; Martínez Hellín Á; Blum Domínguez A; Caballero Navarro G; Cáceres Sansaloni A; Guerrero Fernández L; Muñoz Linares C; Gasior Kabat M; Pérez López R; Fernández Rodríguez Á; Martínez Bilbao C; Cobo Rodríguez MT; Díaz Á; Durán MA; Santaliestra Tomas M; García-Gutierrez V; Magro Mazo E; Hernández-Boluda JC; Segura A; Raya JM; Navas Elorza B; Osorio S
Ann Hematol; 2023 Feb; 102(2):447-456. PubMed ID: 36422672
[TBL] [Abstract][Full Text] [Related]
57. JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.
Duletić AN; Dekanić A; Hadzisejdić I; Kusen I; Matusan-Ilijas K; Grohovac D; Grahovac B; Jonjić N
Coll Antropol; 2012 Sep; 36(3):859-65. PubMed ID: 23213945
[TBL] [Abstract][Full Text] [Related]
58. [Myeloproliferative neoplasms - Update on diagnosis and treatment].
Meyer SC; Drexler B; Skoda RC
Ther Umsch; 2019; 76(9):487-495. PubMed ID: 32157965
[TBL] [Abstract][Full Text] [Related]
59. How myeloproliferative neoplasms patients' experience and expectations differ from physicians': the international MPN Landmark survey.
Byun JM; Bang SM; Choi EJ; Eom KS; Jung CW; Kim HS; Park J; Choi CW
Korean J Intern Med; 2022 Mar; 37(2):444-454. PubMed ID: 35272443
[TBL] [Abstract][Full Text] [Related]
60. Management of MPN beyond JAK2.
Harrison CN; Garcia NC
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):348-54. PubMed ID: 25696878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]